TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04691375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY314
Description: Dose of PY314 as a single agent given in a standard 3+3 design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY314
Description: Dose of PY314 as a single agent given in a standard 3+3 design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY314
Description: Dose of PY314 as a single agent given in a standard 3+3 design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY314
Description: Dose of PY314 as a single agent given in a standard 3+3 design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy: PY314 + Pembrolizumab
Description: Dose of PY314 alone and given in combination with pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy: PY314 + Pembrolizumab
Description: Dose of PY314 alone and given in combination with pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy: PY314 + Pembrolizumab
Description: Dose of PY314 alone and given in combination with pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy: PY314 + Pembrolizumab
Description: Dose of PY314 alone and given in combination with pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy: PY314 + Pembrolizumab
Description: Dose of PY314 alone and given in combination with pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy: PY314 + Pembrolizumab
Description: Dose of PY314 alone and given in combination with pembrolizumab
Study: NCT00665834

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rosuvastatin
Description: rosuvastatin 20 mg from day 0 to (maximum) day 6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 20 mg from day 0 to (maximum) day 6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: rosuvastatin 20 mg from discharge until the end of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin 80 mg from discharge until the end of the study
Study: NCT01942109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torasemide
Description: Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
Study: NCT04244734

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care treatment
Description: All evaluations are the same in both groups:~Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment:A daily session from Monday to Friday of 40 minutes according to patient functional status: Passive or active-assisted or active mobilizations, muscle enhancement, respiratory physiotherapy and inspiratory muscle training at 40% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Treatment Protocol-MotoMED®
Description: Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment: A daily session from Monday to Friday of 40 minutes (5 minutes of warm-up, 30 of training and 5 of cooling). Combined quadriceps / biceps femoris electrotherapy: at 200-350μs intensity. Respiratory physiotherapy with the objectives: Airway permeabilization and inspiratory muscle training at 60% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)
Study: NCT03434834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical coherence tomography
Description: OCT measurements of 5 locations in the esophagus
Study: NCT04200677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biphasic current (100 Hz) with 2ms pulse width applied to the Tibial Nerve
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 2 ms, Ton: 6 s, Toff: 18 s)
Study: NCT01535482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: Cognitive therapy (CT) will consist of 12 to 16 individual CT sessions on a weekly basis plus 3 booster sessions.
Study: NCT04200677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monophasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Monophasic current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biphasic current (100 Hz) with pulse width 0.5ms applied to the Triceps Surae muscle Belly
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biphasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current , 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
Study: NCT01535482

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced usual care (EUC) will consist of the usual care that individuals receive for suicide prevention in the community, assessment and referral services provided by study staff, and weekly telephone calls lasting 15-30 minutes provided by study therapists to ensure patient safety and to provide some support.
Study: NCT00272181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxinium
Description: Intratumoral administration of Proxinium directly to target tumors.
Study: NCT02052973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propolis varnish
Description: Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
Study: NCT04200677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biphasic current (100 Hz) with 2ms pulse width applied to the Triceps Surae Muscle Belly
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current , 100 Hz, pulse duration 2 ms, Ton: 6 s, Toff: 18 s)
Study: NCT03589742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AblaView® Ablation Catheter
Description: The AblaView® Ablation Catheter is a regular RF ablation catheter with the same physical characteristics and the same biocompatible materials, with an 8 French (2.66 mm) sheath and 180º deflection angle. The tip of the catheter has 15 holes distributed around it where the irrigation will be delivered into the patient's blood. The front irrigation hole will deliver at the same time the infrared light for the OCR system.
Study: NCT01259011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the SPIRIT intervention
Description: the SPIRIT intervention (Sharing the Patient's Illness Representation to Increase Trust) to improve discussions about end-of-life care between patients and their surrogate decision makers
Study: NCT02464982

Intervention type: PROCEDURE
Intervention: Tattoo
Description: tattoo device with EC standards, and sterile single-use only needle
Study: NCT01958086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural Communication System
Description: NeuroPort Arrays allow for the local recording of cerebral cortex. The Neural Communication system is primarily composed of two NeuroPort Arrays. The two arrays of one MultiPort device will be placed in the primary motor cortex for recording (Platinum-tipped electrodes); and the two arrays of the additional MultiPort device be placed in the superior parietal lobule for recording (Platinum-tipped electrodes). Each MultiPort device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D) or 4 mm x 4 mm x 1.0 mm, and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array.
Study: NCT04103450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: oral administration
Study: NCT04200677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biphasic current (25 Hz) with 0.5ms pulse width applied to the Triceps Surae Muscle Belly
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 25 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
Study: NCT01360944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004
Description: once daily, topical, 100 microgram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004
Description: once daily, topical, 100 microgram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004
Description: once daily, topical, 100 microgram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004
Description: once daily, topical, 100 microgram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004
Description: once daily, topical, 100 microgram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004
Description: once daily, topical, 100 microgram

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: reference
Description: once daily, 100 microgram
Study: NCT02386956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active stretching
Description: 10 minutes of active stretching of the posterior muscle chain with RPG techniques

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching
Description: 10 minutes of dynamic stretching of the sciatic nerve and the posterior muscle chain with manual techniques of mobilization the nerves
Study: NCT01360944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reference
Description: once daily, 100 microgram
Study: NCT02902744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILUVIEN®
Description: Patients will receive Iluvien as the standard of care treatment for diabetic macular edema.
Study: NCT02221180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]
Description: Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]
Description: Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.
Study: NCT02386956

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 10 minutes with the patient lying on a machine off of magnetotherapy
Study: NCT01139151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 Day Thiarabine
Description: Starting dose 70 mg/m\^2 IV over 1 hour (±15 minutes) daily x 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Day Thiarabine
Description: Starting dose 40 mg/m2 IV over 1 hour (±15 minutes) daily x 5
Study: NCT02221180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]
Description: Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.
Study: NCT04342247

Intervention type: DRUG
Intervention: external testosteron
Description: external testosteron
Study: NCT02221180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]
Description: Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.
Study: NCT01180127

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol containing food product
Description: 12 weeks, 2X/day, 20g serving

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol containing food product
Description: 12 weeks, 2X/day, 20g serving

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: 4X/week, 1 hour/session at 75% maximum HR
Study: NCT02221180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.
Study: NCT01180127

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: 4X/week, 1 hour/session at 75% maximum HR

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Food product lacking flavanol
Description: 20 g serving, 2X/day, food additive lacking flavonol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Food product lacking flavanol
Description: 20 g serving, 2X/day, food additive lacking flavonol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait list control
Description: 12 week wait list control condition during which participants abstain from aerobic exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait list control
Description: 12 week wait list control condition during which participants abstain from aerobic exercise
Study: NCT02298621

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pomegranate juice
Description: Randomized clinical trial or RCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pomegranate juice
Description: Randomized clinical trial or RCT

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Randomized clinical trial or RCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Randomized clinical trial or RCT
Study: NCT00922961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample taken for the analysis of the rate of CD8 T-Lymphocyte Apoptosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical exam
Description: Assessment of the esthetic score, and the late cutaneous side effect by 2 physicians
Study: NCT03026179

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Play Nicely
Description: Play Nicely is a multimedia program that teaches parents about appropriate methods to discipline.
Study: NCT00646386

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 40 mg eow Week 0 - Week 24

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for adalimumab
Description: 40 mg eow Week 0 - Week 24
Study: NCT02175173

Intervention type: DRUG
Intervention: Rufinamide
Description: Administration of Inovelon 100mg or 200mg Tablets
Study: NCT01098422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yttrium-90 Radioactive Resin Microspheres
Description: An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.
Study: NCT01968980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: 150 mg every 2 weeks, subcutaneous injection, 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection every 2 weeks for 12 months
Study: NCT02164409

Intervention type: PROCEDURE
Intervention: Endoscopy tissue collection
Description: The investigational part of this study is the requirement for an additional biopsy from a site that is already being biopsied at the time of a routine endoscopy. Any patients who develop bleeding following their routine clinical biopsies will not undergo any additional research biopsies.

Intervention type: PROCEDURE
Intervention: Endoscopy tissue collection
Description: The investigational part of this study is the requirement for an additional biopsy from a site that is already being biopsied at the time of a routine endoscopy. Any patients who develop bleeding following their routine clinical biopsies will not undergo any additional research biopsies.
Study: NCT00922129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus (Rapamune)
Description: Started at 5 mg (Target levels 6-10mg/mL), Daily, PO, 24 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin (Neoral) or Tacrolimus (Prograf)
Description: Cyclosporin: 3-4 mg/kg, BID, PO, 24 months~Tacrolimus: 0-.038-0.045 mg/kg, BID, PO, 24 months
Study: NCT03383666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseRider® Aneurysm Neck Reconstruction Device
Description: Neck Reconstruction Device
Study: NCT00549159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Balloon Endometrial Ablation
Description: Thermal balloon endometrial ablation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical Resection of the Endometrium
Description: Transcervical resection of the endometrium
Study: NCT01606150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% lidocaine
Description: 0.1 ml/kg of 1% lidocaine injected over lumbar puncture needle insertion site 2 minutes prior to procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical lidocaine
Description: 1 gram placed over lumbar puncture needle insertion point 30 minutes prior to procedure
Study: NCT03124186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S88 Dual Output Stimulator by Grass Technologies
Description: Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S88 Dual Output Stimulator by Grass Technologies
Description: Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
Study: NCT03339596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: 40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 4 times as intravenous infusions over 15 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
Study: NCT03381989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASHI_INTECC Astato XS 20 0.014 guidewire
Description: A coaxial traversal guiding catheter system (typically tandem catheters) directs electrosurgery devices (typically a rigid 0.014 guidewire inside a polymer jacket wire convertor) against the base of the coronary cusp targeted for laceration, using fluoroscopic and/or echocardiographic guidance. Traversal is accomplished by transcatheter electrosurgery by connecting the back end of the 0.014 guidewire to an electrosurgery pencil during short bursts of pure, cutting radiofrequency energy at ap-proximately 30W. The guidewire is repositioned as needed until it crosses the aortic leaflet and is snare-retrieved and externalized. Laceration is performed by positioning the laceration surface along the intended leaflet base, and applying tension on both free ends of the guidewire while simultaneously apply electrosurgery energy (typically 70W) in short bursts, until the laceration is complete and the guidewire is free.
Study: NCT00790673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF 102
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF 102
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF 102
Description: Oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules